New Drug Application | List of Frontiers open access articles

Original Research

Published on 15 Dec 2022

ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK

in Pharmacology of Anti-Cancer Drugs

Peiran Song
Gang Bai
Shingpan Chan
Tao Zhang
Linjiang Tong
Yi Su
Yanyan Shen
Yi Chen
Yingqiang Liu
Mengzhen Lai

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1071114

3,872 views
1 citation

Original Research

Published on 31 Mar 2023

A mass balance study of [14C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans

in Drug Metabolism and Transport

Hua Zhang
Shu Yan
Yan Zhan
Sheng Ma
Yicong Bian
Shaorong Li
Junjun Tian
Guangze Li
Dafang Zhong
Xingxing Diao

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1116073

4,752 views
8 citations

Review

Published on 07 Nov 2025

Pathways and challenges in the clinical translational of radiopharmaceuticals for pediatric investigations

in Nuclear Medicine

Erik Stauff
Hanieh Karimi
Heidi H. Kecskemethy
Thomas H. Shaffer
Reza Vali
Lauren W. Averill
Xuyi Yue

Frontiers in Medicine

doi 10.3389/fmed.2025.1658588

2,103 views
1 citation

Policy and Practice Reviews

Published on 09 Oct 2024

Pathways for non-manufacturers to drive generic drug repurposing for cancer in the U.S.

in Drugs Outcomes Research and Policies

Devon Crittenden
Raquel Gallagher
Fernanda Milans del Bosch
David M. Fox
Laura B. Kleiman

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1419772

7,460 views
2 citations

Systematic Review

Published on 21 Apr 2022

Biologics for Non-Cancer Dermatological Diseases: Analysis on China’s Clinical Trial Registration Trend From 2016 to 2020

in Inflammation Pharmacology

Beibei Zhu
Yi Liu
Jing Li
Qi Ni
Zheng Yin
Junli Zhu
Ken Chen
Xueyuan Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2022.817065

5,794 views
4 citations

Original Research

Published on 25 Feb 2020

Adaptation for Regulatory Application: A Content Analysis of FDA Risk Evaluation and Mitigation Strategies Assessment Plans (2014–2018) Using RE-AIM

in Public Health Education and Promotion

Gita A. Toyserkani
Linda Huynh
Elaine H. Morrato

Frontiers in Public Health

doi 10.3389/fpubh.2020.00043

7,741 views
10 citations

Articles

ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK

A mass balance study of [14C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans

Pathways and challenges in the clinical translational of radiopharmaceuticals for pediatric investigations

Pathways for non-manufacturers to drive generic drug repurposing for cancer in the U.S.

Biologics for Non-Cancer Dermatological Diseases: Analysis on China’s Clinical Trial Registration Trend From 2016 to 2020

Adaptation for Regulatory Application: A Content Analysis of FDA Risk Evaluation and Mitigation Strategies Assessment Plans (2014–2018) Using RE-AIM